Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an
information session dedicated to its planned STAR pivotal trial and
scleroderma, featuring principal investigator Dr. Dinesh Khanna. The
session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the
Prescott Hotel, 545 Post Street, San Francisco, Room 736.
The STAR pivotal trial is expected to commence in 2015 and will evaluate
Cytori Cell Therapy™ as a potential treatment for impaired hand function
in scleroderma, a rare autoimmune disease affecting approximately 50,000
people in the United States.
The January 14th informational session will provide an opportunity to
understand the epidemiology of scleroderma and the planned trial design,
to review previous trial data and other scientific support, and to learn
about the scleroderma market opportunity.
About Dr. Dinesh Khanna
Dinesh Khanna, MD, MS, the Frederick G.L. Huetwell Professor of
Rheumatology and an Associate Professor of Internal Medicine, is the
director of the University of Michigan Scleroderma Program. He has also
served as Clinical Director of UCLA’s Scleroderma Clinic.
Dr. Khanna is the author of over 160 peer-reviewed publications and book
chapters. He has won numerous awards, including the 2007 Spirit of
Leadership Award and the 2011 “Best Doctor of the Year” award from the
Scleroderma Foundation. He is board certified in rheumatology. Dr.
Khanna is currently funded by the National Institutes of Health and is
particularly interested in the design of clinical trials and assessing
patient reported outcomes in patients with scleroderma and leading novel
international clinical trials in scleroderma.
Dr. Khanna is a fellow of the American College of Rheumatology. He was
elected by his peers to the 2011-2012 Best Doctors in America, which
recognizes the area’s top clinicians.
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing
autologous cell therapies from adipose tissue to treat a variety of
medical conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving blood
flow, modulating the immune system, and facilitating wound repair. As a
result, Cytori Cell Therapy™ may provide benefits across multiple
disease states and can be made available to the physician and patient at
the point-of-care through Cytori’s proprietary solutions. For more
information: visit www.cytori.com
or follow Cytori on Twitter www.twitter.com/cytori.
Copyright Business Wire 2014